Skip to Content

View Additional Section Content

A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer and a response or stable disease to platinum therapy

For more information on this trial, click the link below.

Clinical Trial Categories

  • Ovarian Cancer
Hanjani Institute for Gynecologic Oncology at 215-885-0220


  • Hanjani Institute for Gynecologic Oncology
    Asplundh Cancer Pavilion
    3941 Commerce Ave
    Willow Grove, PA 19090
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory


Schedule a